Dr_Jamie_Murphy

Dr_Jamie_Murphy Specalist cancer surgeon in London with clinical & research interest in advanced colorectal and peritoneal cancers

The integration of AI into bowel cancer treatment provides a promising future where treatment is increasingly tailored, ...
06/08/2025

The integration of AI into bowel cancer treatment provides a promising future where treatment is increasingly tailored, precise, and effective.

In a recent Cancer Research UK‑led study, an AI‑based CD3 Score test analysed the density of CD3 immune cells in stage II bowel cancer tissues and accurately stratified patients by risk of recurrence over 5 years.

This breakthrough provides a more precise tool for deciding whether adjuvant chemotherapy is needed, helping some patients safely avoid unnecessary treatment and its side effects. It’s a promising step towards personalising care for early-stage colorectal cancer patients.

Read more here and see how it may inform HIPEC‑related decision-making - https://drjamiemurphy.co.uk/news/how-ai-is-helping-with-bowel-cancer-treatment/

πŸ”₯πŸ”₯πŸ”₯The STELLAR‑303 study πŸ”₯πŸ”₯πŸ”₯is a PhaseΒ 3 clinical trial comparing a πŸ†• drug combination β€”zanzalintinib (an experimental t...
28/06/2025

πŸ”₯πŸ”₯πŸ”₯The STELLAR‑303 study πŸ”₯πŸ”₯πŸ”₯is a PhaseΒ 3 clinical trial comparing a πŸ†• drug combination β€”zanzalintinib (an experimental tyrosine kinase inhibitor) plus atezolizumab (an immunotherapy drug) β€” against regorafenib, a currently available standard treatment, for patients with metastatic (mCRC). STELLAR‑303 recruited approximately 900 adults with mismatch repair proficient (pMMR / MSS) mCRC, who had cancer progression after all standard options had been exhausted (5FU, capecitabine, irinotecan, oxaliplatin Β± Avastin, cetuximab or panitumimab if RAS wild-type, and BRAF-targeted therapy if applicable). Exelixis, the company πŸƒ this trial, announced this week that STELLAR‑303 met its primary endpoint, demonstrating a statistically significant improvement in overall survival. The πŸ“ˆ have not yet been released from the trial and will be presented in the coming weeks. However, the hope is this is a step toward being able to offer to the c.85% of mCRC patients who aren’t currently eligible due to having mismatch repair proficient disease. Discussions are being had with the πŸ‡ΊπŸ‡Έ FDA so this is 1️⃣ to ⌚️ 🀞🀞🀞

πŸ”₯ So 1️⃣ of the studies presented at ASCO 2025 many of you will have read about in the press is The Challenge trial πŸ”₯ Th...
03/06/2025

πŸ”₯ So 1️⃣ of the studies presented at ASCO 2025 many of you will have read about in the press is The Challenge trial πŸ”₯ This randomised patients with high risk stage 2 or stage 3 who had completed after surgery to either have a structured exercise prescription (SEP) or to receive health educational materials (HEM). 445 patients were randomised to SEP and 444 patients were randomised to HEM. Most patients in the SEP group could hit their πŸƒβ€β™‚οΈ 🎯 by adding a 45-60 min brisk walk to their routine 3-4 βœ–οΈ per week. Both overall survival and disease πŸ†“ survival were significantly improved in the SEP group, which seems to be predominantly due to a decrease in cancer recurrence in liver. The authors indicate that for every 14 people who participated in SEP 1️⃣ 🧍 was prevented from dying of cancer. Furthermore the risk of developing a second πŸ†• cancer in the breast, prostate or colon was lower in the SEP group. The assessment of the authors or this πŸ“– is that the SEP may actually have a greater impact on survival than post surgery chemo! This is really exciting data and this represents a πŸ†• standard of care for people with . However it does mean we will need lots more physiotherapists to deliver these SEP, but given the impact of this is something that must be done πŸƒβ€β™€οΈπŸ’ͺπŸ‹οΈβ€β™‚οΈ

🚨 πŸ†• πŸ“– update from ASCO 25! 🚨 This πŸ“– looked at a πŸ†• combination of drugs (encorafenib plus cetuximab, with or without chem...
31/05/2025

🚨 πŸ†• πŸ“– update from ASCO 25! 🚨 This πŸ“– looked at a πŸ†• combination of drugs (encorafenib plus cetuximab, with or without chemotherapy) to treat patients with stage 4 and a BRAF V600E mutation. A previous πŸ“– showed that adding these πŸ†• drugs to standard chemotherapy worked better than standard treatment alone, so the πŸ‡ΊπŸ‡Έ FDA gave this πŸ†• combination early approval. Researchers have now released updated results.

Adding encorafenib plus cetuximab to chemotherapy (FOLFOX) helped people live longer without their cancer getting worse compared to standard chemotherapy (average 12.8 months vs. 7.1 months). It also helped people live longer overall (average 30.3 months vs. 15.1 months). Serious side effects happened in about 46% of people taking the πŸ†• drugs plus chemotherapy, compared to 39% with standard chemotherapy. The types of side effects seen were what would be expected for these treatments.

For people with mutated stage 4 , starting treatment with the πŸ†• drug combination and chemotherapy helped them live longer and kept their cancer under control longer than compared to standard treatment!

🌟

Results of long awaited CAIRO6 trial being reported at ASCO ! Congratulations to trial team for completing this absolute...
24/05/2025

Results of long awaited CAIRO6 trial being reported at ASCO ! Congratulations to trial team for completing this absolutely critical study. While will need to wait for the presentation, the abstract suggests moving to the Dutch strategy of CRS HIPEC up front rather than systemic chemotherapy does not decrease overall survival. Look forward to seeing results so can understand - what proportion of patients didn’t receive adjuvant chemotherapy due to surgical complications, the outcome of patients with RAS / RAF mutations, and discussions regarding optimal management stragey for patients with MMR deficient disease.

This week performed first Gastric PIPAC treatment in England as part of PICCOS study following our colleagues in Wales....
26/04/2025

This week performed first Gastric PIPAC treatment in England as part of PICCOS study following our colleagues in Wales. Massive team effort. Thanks to all those who supported it & most importantly the patients who put their trust in the trial

On 8 April the πŸ‡ΊπŸ‡Έ Food and Drug Administration (FDA) approved a πŸ†• first line combination therapy for certain advanced co...
13/04/2025

On 8 April the πŸ‡ΊπŸ‡Έ Food and Drug Administration (FDA) approved a πŸ†• first line combination therapy for certain advanced colorectal cancers. This treatment pairs 2️⃣ immunotherapy drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), for that cannot be surgically removed or that has spread to other parts of the body.

Colorectal cancer can sometimes have genetic features called β€œMSI-H” (microsatellite instability-high) also known as β€œdMMR” (deficient mismatch repair). These features make the cancer more responsive to immunotherapies. The newly approved combination therapy targets these specific cancer types, enhancing the body’s immune response to fight the cancer cells more effectively.

The FDA approval is based on results from the CheckMate 8HW clinical trial, which compared the πŸ†• combination therapy to standard chemotherapy. The median progression-free survival (πŸ•°οΈ during and after treatment where the disease does not grow) was not reached in the immunotherapy group, indicating πŸ‘ disease control, as compared to an average of 5.8 months in the standard chemotherapy group.

The FDA approval not only provides a πŸ†• treatment option for patients with MSI-H or dMMR colorectal cancer but it also signifies a shift towards more personalised cancer therapies. For patients and families affected by this type of colorectal cancer, this development offers renewed hope and underscores the importance of genetic testing in guiding cancer treatment decisions.

off press! 4️⃣ days ago the πŸ‡ΊπŸ‡Έ Food and Drug Administration granted fast track designation to a πŸ†• treatment strategy for...
12/01/2025

off press! 4️⃣ days ago the πŸ‡ΊπŸ‡Έ Food and Drug Administration granted fast track designation to a πŸ†• treatment strategy for . Invikafusp alfa has been shown to activate very specific parts of the immune system (VΞ²6/VΞ²10 TCR-expressing CD8+ and CD4+ effector memory T cells). These particular immune cells have been shown in πŸ”¬ studies to be able to kill tumour cells designated as having high tumour mutational burden (TMB) that are resistant to immunotherapy. The phase 1/2 START002 πŸ“– looked at Invikafusp alfa in 35 patients with an average of 4 different lines of chemotherapy treatment. Stable disease was reported in half (56%) of patients with 8 patients experiencing tumor shrinkage, including 2 βœ… partial responses. Now I should highlight 2️⃣ things - 1) this is only for people with TMB high cancer (similar to but not same as MSI / dMMR) which is not something routinely checked in πŸ‡¬πŸ‡§; and 2.) that despite FDA approval of Invikafusp alfa these are very early πŸ“ˆ. An πŸ‡ΊπŸ‡Έ Phase 2 clinical trial of Invikafusp alfa is underway. If these πŸ“ˆ are βœ… we could be πŸ‘€ at a πŸ†• class of treatment for tumor types that are insensitive or resistant to immunotherapy.🀞🀞🀞

Exciting early πŸ“ˆ have been reported in past few days from a Phase 2 πŸ“– (CRDF-004) πŸ‘€ at potential πŸ†• treatment options for ...
18/12/2024

Exciting early πŸ“ˆ have been reported in past few days from a Phase 2 πŸ“– (CRDF-004) πŸ‘€ at potential πŸ†• treatment options for patients with that have either KRAS or NRAS mutations. The CRDF-004 trial is ongoing and is assessing a πŸ†• drug, Onvansertib, which inhibits the PLK1 gene. Thirty patients have been randomised so far to receive either - 1.) FOLFIRI Avastin alone (standard treatment); 2.) FOLFIRI Avastin with 20 mg Onvansertib; or 3.) FOLFIRI Avastin with 30 mg Onvansertib. The primary outcome measure for this πŸ“– is objective response rate (ORR) and the reported πŸ“ˆ cover πŸ†™ until 26 November 2024. The ORR for all patients receiving Onvansertib was 57% with what seem to be no cases of progression, as compared to group 1 (standard treatment) that had a 33% ORR. Patients receiving the higher dose of Onvansertib had a 64% ORR as compared to those who had the lower Onvansertib dose who had a 50% ORR. The first patients were treated in CRDF-004 c. 7 months ago but progression πŸ†“ survival πŸ“ˆ are still awaited and will come with the formal trial results. Options for people with stage 4 KRAS / NRAS mutated colorectal cancer in πŸ‡¬πŸ‡§ are a bit more limited than for those who don’t have those mutations so I’m very pleased to see positive πŸ‘€ studies happening in this area. ⌚️ this space…

βœ‹ WEBINAR βœ‹ Artificial Intelligence (AIS)πŸ‘‰ Register the webinar now:https://lnkd.in/gTDDw9GT πŸ‘‰ Two ways to access the ...
17/12/2024

βœ‹ WEBINAR βœ‹
Artificial Intelligence (AIS)

πŸ‘‰ Register the webinar now:https://lnkd.in/gTDDw9GT

πŸ‘‰ Two ways to access the webinar:
1. Spatial:Β https://lnkd.in/gjGQM_a8

2. Zoom Link:Β https://lnkd.in/gABqeWqJ
Β Β  Zoom ID: 851 7777 8688

Time
December 18, 2024
2:00 PM (CET)
9:00 PM (Beijing, CET+7)
1:00 PM (London, CET-1)

Tickets are now available for the inaugural Cleveland Clinic London Re**al Cancer Study Day ! Hosted by and
11/12/2024

Tickets are now available for the inaugural Cleveland Clinic London Re**al Cancer Study Day ! Hosted by and

A recently published phase II πŸ“– from πŸ‡ΊπŸ‡Έ evaluated a πŸ†• chemotherapy drug Onvansertib (a PLK1 inhibitor) combined with sta...
07/11/2024

A recently published phase II πŸ“– from πŸ‡ΊπŸ‡Έ evaluated a πŸ†• chemotherapy drug Onvansertib (a PLK1 inhibitor) combined with standard chemotherapy when used for patients with KRAS-mutated . Onvansertib was used in combination with FOLFIRI Avastin for patients who had already received first-line oxaliplatin based chemotherapy. At total of 53 patients with were recruited to this πŸ“–. The results of the πŸ“– demonstrated an overall response rate of 26.4%, with responses lasting an average of 11.7 months. Interestingly, patients who hadn’t received Avastin as part of their first-line treatment responded better to the Onvansertib combination. These patients had an improved overall response rate of 76.9% and a longer progression-πŸ†“ survival of 14.9 months when compared to those with previous Avastin exposure. The results of this πŸ“– suggest that prior Avastin exposure may reduce Onvansertib’s effectiveness. For that reason the πŸ“– authors suggested Onvansertib should now be tested as first-line chemotherapy for KRAS mutated colorectal cancer. This is going to happen in a forthcoming πŸ“– (NCT06106308 (https://www.clinicaltrials.gov/ct2/show/NCT06106308). 1️⃣ to ⌚️ !!!!

Address

24 Portland Place
London
W1B1LU

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+442034237500

Website

Alerts

Be the first to know and let us send you an email when Dr_Jamie_Murphy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr_Jamie_Murphy:

Shortcuts

Share

Category